

From: [Bruce Forrest](#)
To: [Stephen E de Laszlo](#)
Subject: Pneumococcal Conjugate Vaccine IP Opportunity
Date: Monday, October 11, 2021 1:31:23 PM
Attachments: [US11058757.pdf](#)

Dear Stephen,

My apologies for reaching out to you directly, but I'd like to explore any interest that Merck might have in the IP that my team and I have developed in the field relating to serotype compositions of pneumococcal conjugate vaccines. As you might recall, Merck explored some of this IP back in 2018 where we were looking to develop it in Liffey Biotech Limited. So, it may not be entirely unfamiliar to the firm.

The IP is now in Pogona, LLC, and we have one patent now granted in August, expecting the allowance of a second patent this year, and we are beginning the process of generating divisional filings etc. to expand on the original applications and PCT filings.

While we have begun the process of raising funds to develop a next generation PCV from this IP, given our team's enormous experience in the development, approval, manufacturing and commercialization of PCV (all being in previously senior level roles at Pfizer/Wyeth for Prevnar and Prevnar 13 previously), we have also recently been contacted by one private firm, another NASDAQ traded firm, and an attorney representing another yet undisclosed client each with the express interest of exploring our willingness to consider licensing the IP.

It has been a busy few weeks.

This external interest resulted in us giving more serious reconsideration to exploring licensing or partnering opportunities, now that the current generation of PCV have recently been approved by the FDA.

My suspicion is that we have shared interests in a truly novel next generation PCV, and if that is so, we would prefer not to be a hindrance to seeing that come to fruition to our mutual benefit. My preference is for this IP to be with a firm that I know has the wherewithal to see this developed successfully.

I could share a slide set, a two page summary, but since this is about the IP, I have attached the issued patent, and additional patent application numbers for the US, Europe and Japan where applicable.

If there might be some additional interest in exploring any element of this with me, feel free to reach back out.

I am in the NY area, and would be happy to drive and meet at any Merck location. Even informally.

- US Patent Grant: [US11058757](#)
- Priority Date: 03/31/2016

- US Patent Application: 17/347435
- US Patent Application: 16/753597
- Japan Patent Application: 2019-502538
- EP Patent Application: 1776881.9
- EP Patent Application: 18864637.6
- PCT Patent Application PCT/US2018/54391

Kindest Regards,

Bruce

Bruce D. Forrest, MD, MBA
Manager
Pogona, LLC

135 Piermont Avenue
South Nyack, NY 10960

Tel.: (914) 661 6108